PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: AstraZeneca
New Non-Profit Alliance of Big Pharma Firms
By Amy Ritter.
Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog Also tagged Abbott, Big Pharma, biopharm, BMS, Eli Lilly, Genentech, GlaxoSmithKline, Pfizer, Roche, Sanofi Leave a comment
Brennan Departure: What Now for AZ?
AstraZeneca’s shares may have fallen by as much as 6.3% following news of David Brennan’s imminent departure — the biggest intraday decline since December 17, 2010, said Bloomberg — but analysts welcomed his retirement as a good thing. “This will be received positively,” said WestLB’s Mark Belsey. “It’s time for someone to reinvigorate the pipeline.”
With [...]
UK Reacts to AZ Job Cuts
UK Waits for AZ Job Cut Breakdown
As this blog was posted, AstraZeneca was still keeping the world in suspense as to a further breakdown of its announced 7,300 job cuts. The company’s UK staff assembled for a meeting at 10 am, but as of lunchtime there was still no confirmation of the actual numbers , [...]
First Orphan Launch a Challenge for AstraZeneca
Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names.
Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, isn’t [...]
Posted in FDA, Marketing, Safety, Strategy, patient education Also tagged Cancer, Launch, Orphan Drugs, Sales, Ultra Orphan Leave a comment
AstraZeneca's R&D Trimdown, Points to Shift in The Way Big Pharma Invents